Related Experiment Video
Updated: Jul 21, 2026
06:53
Cell Population Analyses During Skin Carcinogenesis
Published on: August 21, 2013
Lymphoscintigraphy with 123I-labelled epidermal growth factor
C Schatten1, N Pateisky, N Vavra
11st Department of Obstetrics and Gynaecology, University of Vienna, Austria.
Lancet (London, England)
|February 16, 1991
Summary
123I-labelled epidermal growth factor (EGF) scans show abnormal uptake in pelvic lymph nodes of advanced cervical cancer patients. This imaging technique identified potential disease in 7 patients missed by conventional radiology.
Area of Science:
- Nuclear medicine imaging
- Oncology
- Radiology
Background:
- Advanced cervical cancer poses significant diagnostic challenges.
- Accurate staging is crucial for effective treatment planning.
Purpose of the Study:
- To evaluate the utility of 123I-labelled epidermal growth factor (EGF) scans for detecting lymph node involvement in advanced cervical cancer.
- To compare the sensitivity of EGF scans with conventional radiological methods.
Main Methods:
- 123I-labelled EGF scans were performed on 14 patients with advanced cervical cancer.
- Imaging was assessed for abnormal lymph node uptake, with optimal visualization occurring 6-8 hours post-injection.
- Results were compared with computerised tomography (CT), ultrasound, and conventional radiology.
Main Results:
- Abnormal lymph node imaging was observed in 11 out of 14 patients (78.6%).
- Specifically, abnormal uptake by pelvic lymph nodes was detected in 11 patients.
- Of these 11, 4 had confirmed disease on CT and ultrasound, while conventional radiology failed to detect disease in the remaining 7.
Conclusions:
- 123I-labelled EGF scans demonstrate potential in identifying lymph node metastases in advanced cervical cancer.
- This imaging modality may detect disease not evident on conventional radiological assessments.
- Further investigation is warranted to establish the role of EGF scans in cervical cancer staging.
